Hearts and Minds Investments (HM1) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
9 Jun, 2026Executive summary
Investment portfolio delivered an 11.7% return for FY24, with improved performance following management changes 18 months ago.
Total comprehensive income after tax was $53.5 million for FY24, down from $63.0 million in FY23.
Share price rose from $2.26 to $2.58, narrowing the discount to NTA and resulting in a 20% total shareholder return for FY24.
Fully franked dividends paid amounted to 14 cents per share, with an increased half-yearly dividend of 7.5 cents declared for October 2024.
$9.4 million paid and $6.4 million provisioned for medical research funding in FY24.
Financial highlights
Investment portfolio up 11.7% for FY24; compound pre-tax return since inception is 9.3% per annum.
Total comprehensive income after tax was $53.5 million for FY24.
Fully franked dividend yield of 5.8% (grossed up 8.3%) on 30 June 2024 share price.
Total shareholder return for FY24 was 20%.
Outlook and guidance
Board remains confident that improved investment performance will continue to narrow the share price discount to NTA.
Ongoing commitment to pay fully franked dividends twice yearly, subject to cash reserves and franking credits.
Latest events from Hearts and Minds Investments
- FY25 saw a 25.5% portfolio return, higher dividends, and strong support for medical research.HM1
H2 20259 Jun 2026 - Half-year profit hit $115.3M, with strong returns and a higher dividend declared.HM1
H1 20255 Jun 2026 - Flat returns and a major write-down led to a sharp profit drop, but the interim dividend was raised.HM1
H1 20265 Jun 2026 - Strong returns, higher dividends, and active management drive performance and philanthropy.HM1
AGM 20243 Feb 2026 - Strong returns, rising dividends, and major medical research funding highlighted at AGM.HM1
AGM 202526 Nov 2025